Download
s00345-020-03272-2.pdf 714,86KB
WeightNameValue
1000 Titel
  • Holmium laser enucleation of the prostate: efficacy, safety and preoperative management in patients presenting with anticoagulation therapy
1000 Autor/in
  1. Deuker, Marina |
  2. Rührup, Jessica |
  3. Karakiewicz, Pierre I. |
  4. Welte, Maria |
  5. Kluth, Luis A. |
  6. Banek, Severine |
  7. Roos, Frederik C. |
  8. Mandel, Philipp |
  9. Chun, Felix K.-H. |
  10. Becker, Andreas |
1000 Erscheinungsjahr 2020
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2020-06-02
1000 Erschienen in
1000 Quellenangabe
  • 39(4):1219-1226
1000 Copyrightjahr
  • 2020
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1007/s00345-020-03272-2 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8124040/ |
1000 Publikationsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • Purpose!#!We evaluated efficacy and safety profile of patients with anticoagulation therapy (AT) undergoing holmium laser enucleation of the prostate (HoLEP).!##!Methods!#!Within our prospective institutional database (11/2017 to 11/2019), we analyzed functional outcomes and 30-day complication rates of HoLEP patients according to Clavien-Dindo classification (CLD), stratified according to specific AT vs. no AT. Further analyses consisted of uni- and multivariate logistic regression models (LRM) predicting complications.!##!Results!#!Of 268 patients undergoing HoLEP, 104 (38.8%) received AT: 25.7% were treated with platelet aggregation inhibitors (PAI), 8.2% with new oral anticoagulants (NOAC) and 4.9% with AT-combinations or coumarins bridged with low molecular weight heparins (LMWH/combination). Patients receiving AT were significantly more comorbid (p < 0.01). Pre- and postoperative maximal flow rates, residual void urine and IPSS at 3 months after surgery were invariably improved after HoLEP for patients with/ without AT. Overall complication rate was 19.5% in patients with no AT vs. 26.1% vs. 27.3 vs. 46.2%, respectively, in patients with PAI, NOAC and LMWH/combination (p < 0.01). Major complications (CLD ≥ 3b) occurred in 6.1% of no AT patients vs. 4.3% vs. 4.5 vs. 0% in patients with PAI, NOAC and LMWH/combination, respectively (p < 0.01). In multivariate LRM, AT was not significantly associated with higher complication rates, whereas high ASA status (OR 2.2, p = 0.04), age (OR 1.04, p = 0.02) and bioptical or incidental prostate cancer (OR 2.5, p = 0.01) represented independent risk factors.!##!Conclusion!#!Despite higher overall complication rates in AT patients, major complications were not more frequent in AT patients. HoLEP is safe and effective in anticoagulated patients.
1000 Sacherschließung
lokal Prostatectomy/adverse effects [MeSH]
lokal Aged [MeSH]
lokal HoLEP
lokal Humans [MeSH]
lokal Prospective Studies [MeSH]
lokal Treatment Outcome [MeSH]
lokal Anticoagulation
lokal Lasers, Solid-State/adverse effects [MeSH]
lokal Middle Aged [MeSH]
lokal Platelet Aggregation Inhibitors/therapeutic use [MeSH]
lokal Bleeding
lokal Transfusion
lokal Original Article
lokal Lasers, Solid-State/therapeutic use [MeSH]
lokal Complications
lokal Male [MeSH]
lokal Clavien–Dindo classification
lokal Prostatic Hyperplasia/surgery [MeSH]
lokal Anticoagulants/therapeutic use [MeSH]
lokal Prostatectomy/methods [MeSH]
1000 Liste der Beteiligten
  1. https://orcid.org/0000-0002-1219-387X|https://frl.publisso.de/adhoc/uri/UsO8aHJ1cCwgSmVzc2ljYQ==|https://frl.publisso.de/adhoc/uri/S2FyYWtpZXdpY3osIFBpZXJyZSBJLg==|https://frl.publisso.de/adhoc/uri/V2VsdGUsIE1hcmlh|https://frl.publisso.de/adhoc/uri/S2x1dGgsIEx1aXMgQS4=|https://frl.publisso.de/adhoc/uri/QmFuZWssIFNldmVyaW5l|https://frl.publisso.de/adhoc/uri/Um9vcywgRnJlZGVyaWsgQy4=|https://frl.publisso.de/adhoc/uri/TWFuZGVsLCBQaGlsaXBw|https://frl.publisso.de/adhoc/uri/Q2h1biwgRmVsaXggSy4tSC4=|https://frl.publisso.de/adhoc/uri/QmVja2VyLCBBbmRyZWFz
1000 Hinweis
  • DeepGreen-ID: 426c7595ddad477aa0e3ca7f75441b9d ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Dateien
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6466832.rdf
1000 Erstellt am 2023-11-17T03:38:02.471+0100
1000 Erstellt von 322
1000 beschreibt frl:6466832
1000 Zuletzt bearbeitet Fri Dec 01 04:56:15 CET 2023
1000 Objekt bearb. Fri Dec 01 04:56:15 CET 2023
1000 Vgl. frl:6466832
1000 Oai Id
  1. oai:frl.publisso.de:frl:6466832 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source